Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.

Collins VL, Marchaim D, Pogue JM, Moshos J, Bheemreddy S, Sunkara B, Shallal A, Chugh N, Eiseler S, Bhargava P, Blunden C, Lephart PR, Memon BI, Hayakawa K, Abreu-Lanfranco O, Chopra T, Munoz-Price LS, Carmeli Y, Kaye KS.

Antimicrob Agents Chemother. 2012 Apr;56(4):2173-7. doi: 10.1128/AAC.05913-11. Epub 2012 Jan 30.

2.
3.
4.

Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.

Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D'Inzeo T, Fadda G, Cauda R, Spanu T.

Antimicrob Agents Chemother. 2007 Jun;51(6):1987-94. Epub 2007 Mar 26. Erratum in: Antimicrob Agents Chemother. 2007 Sep;51(9):3469.

5.

Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing gram-negative bacteria.

Fong JJ, Rosé L, Radigan EA.

Ann Pharmacother. 2012 Mar;46(3):347-52. doi: 10.1345/aph.1Q473. Epub 2012 Mar 6.

PMID:
22395250
6.

Ertapenem for treatment of extended-spectrum beta-lactamase-producing and multidrug-resistant gram-negative bacteraemia.

Lye DC, Wijaya L, Chan J, Teng CP, Leo YS.

Ann Acad Med Singapore. 2008 Oct;37(10):831-4.

7.

Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.

Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC.

Antimicrob Agents Chemother. 2012 Jun;56(6):2888-93. doi: 10.1128/AAC.06301-11. Epub 2012 Mar 19.

8.

Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.

Frakking FN, Rottier WC, Dorigo-Zetsma JW, van Hattem JM, van Hees BC, Kluytmans JA, Lutgens SP, Prins JM, Thijsen SF, Verbon A, Vlaminckx BJ, Cohen Stuart JW, Leverstein-van Hall MA, Bonten MJ.

Antimicrob Agents Chemother. 2013 Jul;57(7):3092-9. doi: 10.1128/AAC.01523-12. Epub 2013 Apr 22.

9.

Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002-2010).

Cantón R, Loza E, Aznar J, Calvo J, Cercenado E, Cisterna R, Romo FG, Hontangas JL, Calvo CR, Barrenechea AI, Tubau F, Weber I, Yuste P, Cavanillas R; SMART-Spain Working Group.

Rev Esp Quimioter. 2011 Dec;24(4):223-32.

10.

Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.

Lee J, Pai H, Kim YK, Kim NH, Eun BW, Kang HJ, Park KH, Choi EH, Shin HY, Kim EC, Lee HJ, Ahn HS.

J Antimicrob Chemother. 2007 Sep;60(3):629-37. Epub 2007 Jun 27.

11.

Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms.

Mody RM, Erwin DP, Summers AM, Carrero HA, Selby EB, Ewell AJ, Moran KA.

Ann Clin Microbiol Antimicrob. 2007 Jun 6;6:6.

12.

Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.

Lee NY, Huang WH, Tsui KC, Hsueh PR, Ko WC.

Diagn Microbiol Infect Dis. 2011 May;70(1):150-3. doi: 10.1016/j.diagmicrobio.2010.12.008. Epub 2011 Mar 12.

PMID:
21398070
13.

In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey.

Kiremitci A, Dinleyici EC, Erben N, Durmaz G, Yargic ZA, Aybey AD, Usluer G.

Expert Opin Pharmacother. 2008 Jun;9(9):1441-9. doi: 10.1517/14656566.9.9.1441 .

PMID:
18518776
14.

Extended-spectrum beta-lactamase-producing organisms.

Falagas ME, Karageorgopoulos DE.

J Hosp Infect. 2009 Dec;73(4):345-54. doi: 10.1016/j.jhin.2009.02.021. Epub 2009 Jul 10. Review.

PMID:
19596491
15.

The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.

Trivedi M, Patel V, Soman R, Rodriguez C, Singhal T.

J Assoc Physicians India. 2012 Aug;60:28-30. Erratum in: J Assoc Physicians India. 2012 Dec;60:20. J Assoc Physicians India. 2012 Sep;60:54. Trivedi, Mayur [corrected to Trivedi, Mayuri].

PMID:
23405518
16.

Which proportion of extended-spectrum beta-lactamase producing strains could be treated by non-carbapenem beta-lactams?

Canoui E, Tankovic J, Bige N, Alves M, Offenstadt G.

Med Mal Infect. 2014 May;44(5):235-7. doi: 10.1016/j.medmal.2014.03.006. Epub 2014 Apr 26. No abstract available.

PMID:
24780641
17.

Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates.

Betriu C, Gómez M, López-Fabal F, Culebras E, Rodríguez-Avial I, Picazo JJ.

Eur J Clin Microbiol Infect Dis. 2010 Sep;29(9):1179-81. doi: 10.1007/s10096-010-0974-3. Epub 2010 Jun 4.

PMID:
20521156
18.

Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children.

Dalgic N, Sancar M, Bayraktar B, Dincer E, Pelit S.

Scand J Infect Dis. 2011 May;43(5):339-43. doi: 10.3109/00365548.2011.553241. Epub 2011 Jan 28.

PMID:
21271945
19.
Items per page

Supplemental Content

Write to the Help Desk